Welcome to our dedicated page for XOMA Royalty Corporation news (Ticker: XOMAP), a resource for investors and traders seeking the latest updates and insights on XOMA Royalty Corporation stock.
XOMA Royalty Corporation (NASDAQ: XOMAP) operates at the intersection of biotechnology and strategic finance, specializing in non-dilutive funding models for therapeutic development. This page serves as the definitive source for XOMA-related news, offering investors and industry professionals timely updates on licensing agreements, portfolio milestones, and financial developments.
Access curated press releases and analysis covering royalty acquisition deals, therapeutic program advancements, and financial performance updates. Our repository includes critical announcements about antibody therapeutics licensing, partnership expansions, and regulatory progress across XOMA's diversified portfolio.
Key content categories include earnings reports, strategic collaborations in oncology and rare diseases, and updates on milestone payments from commercial-stage therapies. Track the company's unique position in biotech finance through verified updates about its royalty aggregation model and portfolio risk management strategies.
Bookmark this page for streamlined access to XOMA's evolving role in enabling drug development through innovative capital solutions. Check regularly for authoritative updates on how the company navigates therapeutic licensing economics while maintaining a balanced asset portfolio.
XOMA Royalty Corporation (NASDAQ: XOMA) has declared quarterly cash dividends for its preferred stockholders. The company will distribute dividends to two classes of preferred shares:
- Holders of 8.625% Series A Preferred Stock (NASDAQ: XOMAP) will receive $0.53906 per share
- Holders of 8.375% Series B Preferred Stock (NASDAQ: XOMAO) will receive $0.52344 per depositary share
Both dividends are scheduled for payment on October 15, 2025, to shareholders of record as of October 3, 2025.
XOMA Royalty (NASDAQ: XOMA) has successfully completed its tender offer to acquire HilleVax (NASDAQ: HLVX). The acquisition terms included $1.95 per share in cash plus one non-tradeable contingent value right (CVR).
The tender offer expired on September 15, 2025, with 39,214,689 shares validly tendered, representing approximately 77.48% of HilleVax's outstanding shares. Following the merger completion, HilleVax became a wholly owned subsidiary of XOMA Royalty. HilleVax shares will cease trading on Nasdaq as of September 17, 2025, and will be delisted and deregistered.
XOMA Royalty Corporation (NASDAQ: XOMA), a biotech royalty aggregator, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. The company's leadership team, including CEO Owen Hughes and CIO Brad Sitko, will deliver a company update presentation on Monday, September 8, 2025, at 9:00 AM ET.
Investors can access the presentation through a webcast link or via the investor relations section of XOMA's website at www.xoma.com.
XOMA Royalty (NASDAQ:XOMA) has announced its subsidiary XRA 5 Corp. will acquire Mural Oncology (NASDAQ:MURA) in an all-cash transaction valued at approximately $36.2 million. Under the agreement, Mural shareholders will receive a base price of $2.035 per share, with potential for an additional $0.205 per share based on Mural's closing net cash position.
The base offer represents a 13.1% premium to Mural's closing price of $1.80 on August 19, 2025, and a 97.6% premium to its undisturbed price of $1.03 on April 14, 2025. The acquisition, recommended by Mural's board, follows a strategic review process and is expected to close by the end of 2025, subject to shareholder and regulatory approvals.
XOMA Royalty (NASDAQ:XOMA) reported Q2 2025 financial results and significant business developments. The company received $29.6 million in royalties and milestones in H1 2025, including $11.7 million in Q2. Notable achievements include the acquisition of multiple companies (Turnstone Biologics, LAVA Therapeutics, and HilleVax) and the $20 million purchase of mezagitamab royalty rights from BioInvent.
Q2 2025 financial highlights include net income of $9.2 million and total income/revenue of $13.1 million. The company ended Q2 with $78.5 million in cash and cash equivalents. Several pipeline advancements were reported, including Rezolute's completion of Phase 3 enrollment for ersodetug and EMA's acceptance of Day One's tovorafenib MAA.
[ "Received $29.6 million in royalties and milestones in H1 2025", "Net income of $9.2 million in Q2 2025, up from $7.4 million in Q2 2024", "Strategic acquisitions of Turnstone Biologics, LAVA Therapeutics, and HilleVax expanding portfolio", "Strong cash position of $78.5 million as of June 30, 2025", "Multiple pipeline advancements including regulatory milestones and Phase 3 trial progress", "Decreased G&A expenses to $7.8 million in Q2 2025 from $11.0 million in Q2 2024" ]XOMA Royalty (NASDAQ: XOMA) has successfully completed its tender offer to acquire Turnstone Biologics (NASDAQ: TSBX). The deal terms included $0.34 per share in cash plus one non-tradeable contingent value right (CVR).
As of the expiration date on August 7, 2025, 17,192,002 shares were validly tendered, representing approximately 74% of Turnstone's outstanding shares. Following the tender offer, XOMA Royalty merged Turnstone with its subsidiary XRA 3 Corp., making Turnstone a wholly owned subsidiary. Turnstone's shares will cease trading on Nasdaq as of August 11, 2025, and will be delisted and deregistered.
XOMA Royalty (NASDAQ: XOMA) has entered into a definitive agreement to acquire LAVA Therapeutics (NASDAQ: LVTX) in a structured deal valued at $1.16 to $1.24 per share in cash, plus a contingent value right (CVR). The CVR entitles shareholders to 75% of net proceeds from LAVA's partnered assets and potential out-licensing of unpartnered programs.
The transaction, expected to close in Q4 2025, requires at least 80% shareholder tender and includes specific closing conditions. As part of the deal, LAVA will discontinue its Phase 1 clinical trial of LAVA-1266 for acute myeloid leukemia and myelodysplastic syndrome. The acquisition adds milestone and royalty economics from LAVA's gamma delta bispecific antibodies portfolio to XOMA Royalty's assets.
XOMA Royalty (NASDAQ: XOMA) has entered into a definitive merger agreement to acquire HilleVax (NASDAQ: HLVX) in a deal that values HilleVax shares at $1.95 in cash per share plus a contingent value right (CVR).
The CVR includes potential additional payments from: (1) excess cash above $102.95 million, (2) 90-100% of savings from Boston office lease obligations, and (3) 90% of proceeds from any norovirus vaccine program sales within specific timeframes. The deal has secured support from 22.9% of HilleVax stockholders, including officers and directors.
XOMA Royalty will commence a tender offer by August 18, 2025, with the acquisition expected to close in September 2025. The deal requires a majority of HilleVax shares to be tendered and maintaining a minimum cash balance at closing.
XOMA Royalty (NASDAQ:XOMA) has announced a definitive merger agreement to acquire Turnstone Biologics (NASDAQ-CM:TSBX). Under the terms of the agreement, XOMA will pay $0.34 in cash per share plus one non-transferable contingent value right (CVR) for each Turnstone share.
The acquisition will proceed through a tender offer starting by July 11, 2025, requiring a majority of outstanding shares to be tendered and meeting certain conditions including minimum cash balance requirements. Approximately 25.2% of Turnstone stockholders have already agreed to tender their shares. The merger is expected to close in August 2025.
FAQ
What is the current stock price of XOMA Royalty Corporation (XOMAP)?
